TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Chen, Chen ^a   Han, Sheng ^a   Meng, Lingxuan ^a   Li, Zhonghua ^a   Zhang, Xue ^a,b   Wu, Anhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN METASTASIS; CANCER PROGNOSIS; CAVERNOUS HEMANGIOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PROMOTER REGION; SURVIVAL RATE; TERT GENE; UPREGULATION; ANALOGS AND DERIVATIVES; ANOXIA; BRAIN NEOPLASMS; CANCER STAGING; DRUG EFFECTS; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY;

ANOXIA; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84903172348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100297     Document Type: Article

References (32)

1. Papadopoulos N, Kinde I, Munari E, Faraj SF, Hruban RH, et al. (2013) TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Res 73: 7162-7167.
2. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
3. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
4. Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Grosschedl R (2000) Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development 127: 469-482.
5. Varea O, Garrido JJ, Dopazo A, Mendez P, Garcia-Segura LM, et al. (2009) Estradiol activates beta-catenin dependent transcription in neurons. PLoS One 4: e5153.
6. Chen L, Han L, Zhang K, Shi Z, Zhang J, et al. (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro Oncol 14: 1026-1036.
7. Nagalski A, Irimia M, Szewczyk L, Ferran JL, Misztal K, et al. (2012) Postnatal isoform switch and protein localization of LEF1 and TCF7L2 transcription factors in cortical, thalamic, and mesencephalic regions of the adult mouse brain. Brain Struct Funct 218: 1531-1549.
8. Zhang Y, Toh L, Lau P, Wang X (2012) Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/beta-catenin pathway in human cancer. J Biol Chem 287: 32494-32511.
9. Han S, Tie X, Meng L, Wang Y, Wu A (2013) PMA and Ionomycin Induce Glioblastoma Cell Death: Activation-Induced Cell-Death-Like Phenomena Occur in Glioma Cells. PLoS One 8: e76717.
10. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
11. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, et al. (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197.
12. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, et al. (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68: 5706-5715.
13. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, et al. (2009) Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27: 3861-3867.
14. Spiegl-Kreinecker S, Pirker C, Filipits M, Lotsch D, Buchroithner J, et al. (2010) O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 12: 28-36.
15. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, et al. (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 12: 116-121.
16. Tang K, Jin Q, Yan W, Zhang W, You G, et al. (2012) Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol 29: 1292-1296.
17. Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, et al. (2010) O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12: 283-288.
18. Shay JW, Zou Y, Hiyama E, Wright WE (2001) Telomerase and cancer. Hum Mol Genet 10: 677-685.
19. Guo X, Wang W, Zhou F, Lu Z, Fang R, et al. (2008) siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther 7: 1555-1560.
20. Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K, et al (2011) Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability. J Pediatr Surg 46: 2221-2227.
21. Wang L, Li PF, Geng M, Cao YC, Yin YC (2013) Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer. Diagn Pathol 8: 33.
22. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, et al. (1998) Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16: 1217-1222.
23. Tchirkov A, Rolhion C, Kemeny JL, Irthum B, Puget S, et al. (2003) Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Br J Cancer 88: 516-520.
24. Oliveira RP, Porter AJ, Dilks K, Landis J, Ashraf J, et al. (2009) Condition-adapted stress and longevity gene regulation by Caenorhabditis elegans SKN-1/Nrf. Aging Cell 8: 524-541.
25. Werner C, Gensch C, Poss J, Haendeler J, Bohm M, et al. (2011) Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis 216: 23-34.
26. Svensson KJ, Welch JE, Kucharzewska P, Bengtson P, Bjurberg M, et al. (2008) Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. Cancer Res 68: 9291-9301.
27. Swanson KR, Rockne RC, Claridge J, Chaplain MA, Alvord EC Jr, et al. (2011) Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology. Cancer Res 71: 7366-7375.
28. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, et al. (2004) Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol Cell Biol 24: 6076-6083.
29. Brandes AA, Bartolotti M (2012) Neuro-oncology: treatment decisions in elderly patients with glioblastoma. Nat Rev Neurol 8: 664-665.
30. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, et al. (2011) Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103: 714-736.
31. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4: 2185.
32. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110: 6021-6026.